- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03912038
Non-caloric Sweeteners Levels in Breast Milk and Newborn's Blood and Effect on Microbiota's Composition.
September 20, 2023 updated by: Marcela Esquivel V, Hospital General de México Dr. Eduardo Liceaga
This study evaluates the presence and quantity of non-caloric sweeteners in newborns umbilical cord blood, and in their mother's breast milk at delivery, at 2 months, 4 months and 6 months of age.
Microbiota composition will be evaluated in milk and in feces of both mother and child.
Study Overview
Detailed Description
The consumption of non-caloric sweeteners (ENC) is increasingly common in our country due to its wide use in all types of food and beverages, even those not labeled as "diet".
Despite its widespread use and being an alternative to the consumption of sugars, several studies have shown that frequent ENC users are also at risk of excessive weight gain, type II diabetes, and cardiovascular diseases.
In addition to this, the consumption of ENC in the early stages of life may predispose to the development of metabolic disorders later in life.The ENC have been shown to have effects on the health of those who consume them, causing metabolic disorders, weight gain and changes in the microbiota.
The newborns, in whom gut microbiota is in the process of being established, influenced by the vaginal and intestinal microbiota of the mother, as well as by the mother's milk, are a vulnerable population in whom the effect of ENC consumption has not been investigated.
This makes it relevant to study the prevalence of ENC in breast milk and umbilical cord blood of their newborns and to evaluate the composition of the intestinal and milk microbiota in order to identify changes attributable to the consumption of ENC.
Study Type
Observational
Enrollment (Actual)
178
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mexico City, Mexico, 06726
- General Hospital of Mexico Dr. Eduardo Liceaga
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Women in labor who come to the service of gynecology and obstetrics General Hospital Mexico.
Usually, they are residents from Mexico City and metropolitan area (Mexico State).
Description
Inclusion Criteria:
- Age 18-40 years old
- Women in labor
- Consent to participate in the study
Exclusion Criteria:
- Pre-term delivery (<30 weeks)
- Metabolic diseases (insulin resistance, diabetes, gestational diabetes)
- Hypertension
- Thyroid disease
- Cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Null or low consumption
No-intervention.
The group consists of women who have reported a null or low consumption of non-caloric sweeteners during late pregnancy.
|
No intervention
|
Moderate consumption
No-intervention.
The group consists of women who have reported a moderate consumption of non-caloric sweeteners during late pregnancy.
|
No intervention
|
High consumption
No-intervention.
The group consists of women who have reported a high consumption of non-caloric sweeteners during late pregnancy.
|
No intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microbiota composition in feces
Time Frame: 2 months
|
Composition of feces microbiota in mother and newborn
|
2 months
|
Microbiota composition in feces
Time Frame: 4 months
|
Composition of feces microbiota in mother and newborn
|
4 months
|
Microbiota composition in feces
Time Frame: 6 months
|
Composition of feces microbiota in mother and newborn
|
6 months
|
Microbiota composition in breast milk
Time Frame: 0 months
|
Composition of breast milk microbiota
|
0 months
|
Microbiota composition in breast milk
Time Frame: 2 months
|
Composition of breast milk microbiota
|
2 months
|
Microbiota composition in breast milk
Time Frame: 4 months
|
Composition of breast milk microbiota
|
4 months
|
Microbiota composition in breast milk
Time Frame: 6 months
|
Composition of breast milk microbiota
|
6 months
|
Non-caloric sweeteners levels at birth
Time Frame: at birth
|
Non-caloric sweeteners levels in milk, plasma, umbilical cord plasma, urine in mg/mL
|
at birth
|
Non-caloric sweeteners levels 2 months follow-up
Time Frame: 2 months after birth
|
Non-caloric sweeteners levels in breast milk and urine in the 2 months follow-up
|
2 months after birth
|
Non-caloric sweeteners levels 4 months follow-up
Time Frame: 4 months after birth
|
Non-caloric sweeteners levels in breast milk and urine in the 4 months follow-up
|
4 months after birth
|
Non-caloric sweeteners levels 6 months follow-up
Time Frame: 6 months after birth
|
Non-caloric sweeteners levels in breast milk and urine in the 6 months follow-up
|
6 months after birth
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Marcela Esquivel, PhD, Hospital General de México Dr. Eduardo Liceaga
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 26, 2018
Primary Completion (Actual)
December 31, 2022
Study Completion (Actual)
December 31, 2022
Study Registration Dates
First Submitted
April 8, 2019
First Submitted That Met QC Criteria
April 9, 2019
First Posted (Actual)
April 11, 2019
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 20, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DI/17/301/05/075
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Microbial Colonization
-
Karolinska InstitutetCompletedMicrobial Colonization and Colorectal Disease
-
NHS FifeUniversity of TurkuUnknownDental Caries | Oral Microbial ColonizationUnited Kingdom
-
University Magna GraeciaRecruiting
-
BLIS Technologies LimitedRecruiting
-
Min-Tze LIONGInternational Islamic University MalaysiaRecruiting
-
VU University of AmsterdamWageningen University and Research; Maag Lever Darm Stichting; Cidrani; WholeFiber and other collaboratorsActive, not recruiting
-
BLIS Technologies LimitedActive, not recruiting
-
Becton, Dickinson and CompanyCompleted
-
Washington University School of MedicineCompletedMicrobial ColonizationUnited States
-
Cairo UniversityUnknown
Clinical Trials on No intervention.
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
Wright State UniversityCompleted